SPRO
Spero Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$157.47M
P/E Ratio
18.13
EPS
$0.15
Beta
1.45
52W High
$3.22
52W Low
$0.52
50-Day MA
$2.36
200-Day MA
$2.33
Dividend Yield
—
Profit Margin
12.80%
Forward P/E
—
PEG Ratio
0.00
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR) bacterial infections and rare diseases in the United States. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $66.80M |
| Gross Profit (TTM) | $28.34M |
| EBITDA | $7.16M |
| Operating Margin | 76.00% |
| Return on Equity | 16.30% |
| Return on Assets | 4.99% |
| Revenue/Share (TTM) | $1.19 |
| Book Value | $1.05 |
| Price-to-Book | 2.38 |
| Price-to-Sales (TTM) | 2.36 |
| EV/Revenue | 1.733 |
| EV/EBITDA | 14.43 |
| Quarterly Earnings Growth (YoY) | 75.30% |
| Quarterly Revenue Growth (YoY) | 174.50% |
| Shares Outstanding | $57.89M |
| Float | $47.33M |
| % Insiders | 22.56% |
| % Institutions | 16.93% |
Historical Volatility
HV 10-Day
54.37%
HV 20-Day
50.43%
HV 30-Day
45.60%
HV 60-Day
46.01%
HV Rank
—
Volatility is currently expanding
Data last updated: 4/9/2026